Mayne Pharma Group (ASX:MYX) reported Wednesday a fiscal first-half loss of AU$0.323 per diluted share, narrowing from AU$0.878 per diluted share a year earlier.
Revenue for the six months ended Dec. 31, 2024, was AU$213.1 million, up 13% from AU$187.9 million a year earlier.
The company said it expects to grow underlying earnings before interest, taxes, depreciation, and amortization in the second fiscal half via revenue growth and cost leverage.
The firm did not declare a dividend for the reported half-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.